Advances have been made in the field of cancer immunotherapy in understanding the role of the host immune response in affecting tumor progression and response to various treatments. Through these advances, two novel immunotherapies were introduced in the clinic for melanoma and prostate cancer.
Methods
This review discusses the available data regarding the immune-modulating effects of various treatments and how they can be utilized in the treatment of breast cancer.
Databases including PubMed and Google Scholar were searched using terms including breast cancer, vaccines, and immunotherapy.
Results
There is increasing evidence to support that certain breast tumors are intrinsically more immunogenic than others. Tumors that elicit more potent cytotoxic T-cell responses tend to have a more favorable prognosis and respond better to chemotherapy than less immunogenic tumors. Many standard treatments used in breast cancer rely in part on their immunogenic effects for their success in eradicating disease. Understanding how to use these agents to effectively augment the antitumor immune response may lead to better outcomes. Finally, many new immunomodulatory agents and vaccines that can reverse the immunosuppression caused by established tumors are in development. Combining these novel agents with current therapies may boost their efficacy.
Conclusions
Immunotherapeutic approaches combined with novel sequences of chemotherapies, radiation, vaccines, and immunomodulating agents hold promise for enhancing the treatment of breast cancer.
References
1.
KirkwoodJ.M., StrawdermanM.H., ErnstoffM.S.. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.J Clin Oncol.1996; 14(1): 7–17.
2.
MikkelsenD.J., RatliffT.L.. Mechanisms of action of intravesical bacillus Calmette-Guerin for bladder cancer.Cancer Treat Res.1989; 46: 195–211.
3.
PetrellaT., QuirtI., VermaS.. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review.Cancer Treat Rev.2007; 33(5): 484–496.
4.
RingdénO., HorowitzM.M.. Graft-versus-leukemia reactions in humans. The Advisory Committee of the International Bone Marrow Transplant Registry.Transplant Proc.1989; 21(1 Pt 3): 2989–2992.
5.
CheeverM.A., HiganoC.S.. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.Clin Cancer Res.2011; 17(11): 3520–3526.
6.
HodiF.S., O'DayS.J., McDermottD.F.. Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med.2010; 363(8): 711–723.
7.
RodyA., HoltrichU., PusztaiL.. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.Breast Cancer Res.2009; 11(2): R15.
8.
AsciertoM.L., KmieciakM., IdowuM.O.. A signature of immune function genes associated with recurrence-free survival in breast cancer patients.Breast Cancer Res Treat.2012; 131(3): 871–880.
9.
YauC., EssermanL., MooreD.H.. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.Breast Cancer Res.2010; 12(5): R85.
10.
DeNardoD.G., BrennanD.J., RexhepajE.. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.Cancer Discov.2011; 1(1): 54–67.
11.
DenkertC., LoiblS., NoskeA.. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.J Clin Oncol.2010; 28(1): 105–113.
12.
ZitvogelL., KeppO., KroemerG.. Immune parameters affecting the efficacy of chemotherapeutic regimens.Nat Rev Clin Oncol.2011; 8(3): 151–160.
13.
DemariaS., VolmM.D., ShapiroR.L.. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.Clin Cancer Res.2001; 7(10): 3025–3030.
14.
TsavarisN., KosmasC., VadiakaM.. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes.Br J Cancer.2002; 87(1): 21–27.
15.
EmensL.A., AsquithJ.M., LeathermanJ.M.. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.J Clin Oncol.2009; 27(35): 5911–5918.
16.
BarokM., IsolaJ., Pályi-KrekkZ.. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.Mol Cancer Ther.2007; 6(7): 2065–2072.
17.
ArnouldL., GellyM., Penault-LlorcaF.. Trastuzumab-based treatment of HER2–positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?Br J Cancer.2006; 94(2): 259–267.
18.
MusolinoA., NaldiN., BortesiB.. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.J Clin Oncol.2008; 26(11): 1789–1796.
19.
PerezE.A., SumanV.J., DavidsonN.E.. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.J Clin Oncol.2011; 29(34): 4491–4497.
20.
DisisM.L., WallaceD.R., GooleyT.A.. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.J Clin Oncol.2009; 27(28): 4685–4692.
21.
MatsumuraS., WangB., KawashimaN.. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells.J Immunol.2008; 181(5): 3099–3107.
22.
ReitsE.A., HodgeJ.W., HerbertsC.A.. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.J Exp Med.2006; 203(5): 1259–1271.
23.
DewanM.Z., GallowayA.E., KawashimaN.. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody.Clin Cancer Res.2009; 15(17): 5379–5388.
24.
SierraJ.R., CeperoV., GiordanoS.. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.Mol Cancer.2010; 9: 75.
25.
MittendorfE.A., CliftonG.T., HolmesJ.P.. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.Cancer.2012; 118(10): 2594–2602.
26.
SolimanH.. Developing an effective breast cancer vaccine.Cancer Control.2010; 17(3): 183–190.
27.
SharmaA., KoldovskyU., XuS.. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.Cancer.2012; 118(17): 4354–4362.
28.
MohebtashM., TsangK.Y., MadanR.A.. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.Clin Cancer Res.2011; 17(22): 7164–7173.
29.
AntoniaS.J., MirzaN., FrickeI.. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.Clin Cancer Res.2006; 12(3 Pt 1): 878–887.
30.
LiaoY.P., SchaueD., McBrideW.H.. Modification of the tumor microenvironment to enhance immunity.Front Biosci.2007; 12: 3576–3600.
31.
OluwadaraO., GiacomelliL., BrantX.. The role of the microenvironment in tumor immune surveillance.Bioinformation.2011; 5(7): 285–290.
32.
LiaoD., LuoY., MarkowitzD.. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model.PLoS One.2009; 4(11): e7965.
33.
PittetM.J.. Behavior of immune players in the tumor microenvironment.Curr Opin Oncol.2009; 21(1): 53–59.
34.
PrendergastG.C.. Immune escape as a fundamental trait of cancer: focus on IDO.Oncogene.2008; 27(28): 3889–3900.
35.
MullerA.J., DuHadawayJ.B., DonoverP.S.. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.Nat Med.2005; 11(3): 312–319.
36.
GhebehH., BarhoushE., TulbahA.. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy.BMC Cancer.2008; 8: 57.
37.
MaoH., ZhangL., YangY.. New insights of CTLA-4 into its biological function in breast cancer.Curr Cancer Drug Targets.2010; 10(7): 728–736.
38.
LeeS., YagitaH., SayersT.J., CelisE.. Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors.Cancer Immunol Immunother.2010; 59(7): 1073–1081.
